Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study

Status Recruiting

Clinical Trial Summary

The Anti-Aβ mAb CED Study is a prospective, longitudinal coverage with evidence development (CED) study using clinical data, patient assessments, and administrative claims data of the Medicare population, conducted in accordance to the National Coverage Determination (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease (AD).

Clinical Trial Description

The Anti-Aβ mAb CED Study is conducted in accordance with the coverage criteria specified in the NCD for patients who have a clinical diagnosis of mild cognitive impairment (MCI) due to AD or mild AD dementia. The complete NCD decision memorandum is available on our website (https://www.cms.gov/medicare-coverage-database/view/ncacal-decisionmemo.aspx?proposed=N&ncai d=305). Study Overview: 1. Clinicians will conduct a neurocognitive evaluation to determine patient eligibility by confirming a clinical diagnosis of MCI due to AD or mild AD dementia, and the presence of amyloid using biomarker testing including imaging (amyloid PET), cerebral spinal fluid (CSF) studies, and/or blood tests. 2. For all Medicare beneficiaries receiving anti-Aβ mAb treatment for MCI due to AD or mild AD dementia, the prescribing clinician will assess the patient's baseline clinical status by cognition and function assessments using validated tools appropriate for use in the MCI with AD and mild AD dementia populations and submit these data to the registry via the dedicated CMS CED submission portal every six months for up to 24 months (five total assessments). 3. In addition to performing the required cognition and function assessments, prescribing clinicians will need to report on the patient's use of anti-platelet and/or anti-coagulation therapy and whether the patient has developed new amyloid related imaging abnormalities (ARIA) since the last assessment data submission. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06058234
Study type	Observational
Source	Centers for Medicare and Medicaid Services/ Coverage and Analysis Group
Contact	CMS CAG
Phone	410-786-2281
Email	CMS_caginquiries@cms.hhs.gov
Status	Recruiting
Phase
Start date	July 6, 2023
Completion date	June 30, 2029

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00243451` - Early Detection of Mild Cognitive Impairment in Individual Patients	N/A
Recruiting	`NCT05872243` - pBFS Guided rTMS Treating Mild Alzheimer's Disease(AD)	N/A
Recruiting	`NCT05417555` - Low Intensity Focused Ultrasound for Mild Cognitive Impairment and Mild Alzheimer's Disease	N/A
Terminated	`NCT01482013` - Safety Study of HPP854 in Subjects With Mild Cognitive Impairment or a Diagnosis of Mild Alzheimer's Disease	Phase 1
Completed	`NCT03186989` - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease	Phase 1/Phase 2
Not yet recruiting	`NCT03752294` - A Novel Therapeutic Target for Alzheimer's Disease in Men and Women 50-85 Years of Age.	Phase 1
Completed	`NCT01013610` - An Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNK 754 in Elderly Volunteers and in Subjects With Mild Alzheimer's Disease	Phase 1
Active, not recruiting	`NCT03234686` - Deferiprone to Delay Dementia (The 3D Study)	Phase 2
Completed	`NCT05233774` - Lomecel-B Effects on Alzheimer's Disease	Phase 2
Withdrawn	`NCT05032482` - WeArable Neuromodulation DeVice for the TrEatment of Alzheimer's Disease	N/A
Terminated	`NCT00582855` - Effect of AQW051 in Patients With Memory Impairment	Phase 2
Completed	`NCT01061489` - Sensory-cognitive and Physical Fitness Training in Mild Cognitive Impairment	N/A
Completed	`NCT01548287` - A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment	Phase 2
Terminated	`NCT00706186` - Safety and Feasibility of Sodium Oxybate in Mild Alzheimer's Disease Patients	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.